CGEM
Cullinan Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
21.68
▲ 0.30 (1.40%)
MARKET · —
Price
Open
21.11
Prev close
21.38
Day high
22.10
Day low
21.40
Volume
738.37K
Market cap
$1.33B
P/E (TTM)
—
52W range
5.68 – 22.54
Trailing performance
Returnvs SPY
1W
+6.59%
+8.0%
1M
+25.46%
+21.7%
3M
+55.08%
+52.0%
6M
+58.83%
+47.8%
YTD
+109.47%
+97.2%
1Y
+190.23%
+170.2%
3Y
+116.37%
+42.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.33B
Enterprise value$1.06B
Revenue (TTM)—
Gross profit—
EBITDA$-221.49M
Net income$-208.34M
EPS (TTM)$-3.11
Free cash flow$-89.23M
Total cash$334.54M
Total debt$2.07M
Book value / share$5.00
Shares outstanding61.46M
Float48.08M
Short % of float22.19%
Dividend yield—
Beta (5Y)-0.02
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.00
PEG ratio—
Price / sales—
Price / book4.34
EV / revenue—
EV / EBITDA-4.80
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-50.30%
Return on assets-31.36%
Debt / equity0.64
Current ratio8.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$219.88M | -$167.38M | -$153.16M | $111.21M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$219.88M | -$167.38M | -$153.16M | $111.21M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.85 | -0.81 | +4.8% |
| Mar 2026 | -0.84 | -0.75 | +11.1% |
| Dec 2025 | -0.84 | -0.77 | +8.2% |
| Sep 2025 | -0.89 | -0.77 | +13.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.85 | 9 | $0 | 0.0% |
| Next quarter | -0.73 | 9 | $11.56M | 0.0% |
| Current year | -3.17 | 9 | $13.88M | 0.0% |
| Next year | -2.71 | 9 | $38.23M | +175.5% |
Analyst targets & ownership
Mean target$32.36
High target$42.00
Low target$23.00
Implied upside49.28%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold0
Sell / Strong sell0 / 0
Held by insiders0.43%
Held by institutions112.56%
Institutions holding252
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-1.31K
Net selling
Buy transactions
8
122.76K shares
Sell transactions
14
124.08K shares
Net transactions
+22
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
273.51K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | MICHAELSON JENNIFER Officer |
CONVERSION | 30.00K | $129.00K | Direct |
| Aug 13, 26 | MICHAELSON JENNIFER Officer |
SELL | 30.00K | $607.80K | Direct |
| Jul 6, 26 | MICHAELSON JENNIFER Officer |
CONVERSION | 4.00K | $17.20K | Direct |
| Jul 6, 26 | MICHAELSON JENNIFER Officer |
SELL | 8.00K | $142.56K | Direct |
| Jun 30, 26 | FENTON MARY KAY Chief Financial Officer |
STOCK | 1.54K | $28.06K | Direct |
| Jun 30, 26 | SUMER JACQUELYN L Officer |
STOCK | 2.47K | $44.98K | Direct |
| May 5, 26 | MICHAELSON JENNIFER Officer |
CONVERSION | 4.00K | $17.20K | Direct |
| May 5, 26 | MICHAELSON JENNIFER Officer |
SELL | 8.00K | $117.00K | Direct |
| Mar 5, 26 | MICHAELSON JENNIFER Officer |
CONVERSION | 4.00K | $17.20K | Direct |
| Mar 5, 26 | MICHAELSON JENNIFER Officer |
SELL | 8.00K | $125.44K | Direct |
| Feb 25, 26 | MICHAELSON JENNIFER Officer |
SELL | 1.78K | $25.17K | Direct |
| Feb 24, 26 | AHMED NADIM Chief Executive Officer |
SELL | 13.52K | $195.56K | Direct |
| Feb 24, 26 | MICHAELSON JENNIFER Officer |
SELL | 5.35K | $76.62K | Direct |
| Feb 24, 26 | SUMER JACQUELYN L Officer |
SELL | 3.60K | $52.11K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AHMED NADIM |
Chief Executive Officer | 390.80K | Sale |
FENTON MARY KAY |
Chief Financial Officer | 127.92K | Stock Award(Grant) |
JONES JEFFREY ALAN |
Officer | 159.97K | Sale |
LYNX1 CAPITAL MANAGEMENT LP |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
MICHAELSON JENNIFER |
Officer | 162.84K | Conversion of Exercise of derivative security |
SAVILL CORRINE |
Officer | 240.99K | Stock Award(Grant) |
SUMER JACQUELYN L |
Officer | 130.56K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
20.45
+6.01% from price
SMA 20
18.89
+14.79% from price
SMA 50
17.76
+22.04% from price
SMA 100
16.14
+34.36% from price
SMA 200
13.90
+55.94% from price
EMA 12
20.27
+6.97% from price
EMA 26
19.10
+13.53% from price
EMA 50
17.98
+20.55% from price
RSI (14)
68.6
Neutral
MACD (12,26,9)
1.17
Hist 0.33
ATR (14)
1.29
5.93% of price
Realised vol 30D
59.1%
Annualised
Bollinger upper
22.50
20, 2σ
Bollinger lower
15.28
20, 2σ
50 / 200 cross
Golden
17.76 vs 13.90
Trend bias
Above 200
+55.94%
Risk profile
Beta vs SPY
1.34
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
59.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-29.8%
Peak to trough
Max drawdown 5Y
-80.6%
Peak to trough
ATR 14
1.29
5.93% of price
Beta (reported)
-0.02
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.14
Call-heavy session
Put / call open interest
7.11
Positioning, not flow
Max pain
18.00
-17.0% from spot
ATM implied vol
123.1%
Nearest strike to spot
Skew (10% OTM)
+23.6%
Puts bid over calls
Call volume
7
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
22.00
21 contracts
Heaviest put OI
18.00
320 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Business Wire · 3d ago
UBS Adjusts Cullinan Therapeutics Price Target to $27 From $24, Maintains Buy Rating
MT Newswires · 5d ago
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · 9d ago
Sector Update: Healthcare Stocks Advance Pre-Bell Thursday
MT Newswires · 9d ago
New Taiho, Cullinan data heats up lung cancer drug battle
BioPharma Dive · 9d ago
Wedbush Adjusts PT on Cullinan Therapeutics to $42 From $39, Maintains Outperform Rating
MT Newswires · 9d ago
Cullinan Therapeutics Says Phase 3 Trial of Experimental Lung Cancer Drug Met Primary Endpoint
MT Newswires · 9d ago
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Business Wire · 10d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.